Holen Sie sich die Stockscreener-App
11.57
0.09%
-0.010
Handel nachbörslich:
11.56
-0.010
-0.09%
Schlusskurs vom Vortag:
$11.58
Offen:
$11.48
24-Stunden-Volumen:
1.05M
Relative Volume:
0.64
Marktkapitalisierung:
$3.64B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-17.00
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
-3.18%
1M Leistung:
+16.63%
6M Leistung:
+52.24%
1J Leistung:
+38.90%
1-Tages-Spanne:
$11.39
$11.71
1-Wochen-Bereich:
$11.39
$12.12
52-Wochen-Spanne:
$6.685
$12.12
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.57 | 3.64B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
118.14 | 52.35B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.07 | 44.67B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.61 | 43.10B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
VTRS
Viatris Inc
|
10.71 | 12.28B | 14.33B | -3.79B | 1.84B | -3.17 |
|
UTHR
United Therapeutics Corp
|
476.59 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Is Amneal Pharmaceuticals Inc. stock a top momentum playMarket Volume Report & Scalable Portfolio Growth Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock trading near support levels2025 Risk Factors & Daily Chart Pattern Signals - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 AllTime Highs & Safe Entry Point Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedVolume Spike & Fast Exit Strategy with Risk Control - newser.com
Amneal gets FDA nod for Iohexol Injection - MSN
Multi asset correlation models including Amneal Pharmaceuticals Inc.Weekly Trend Summary & Fast Entry High Yield Stock Tips - newser.com
Real time breakdown of Amneal Pharmaceuticals Inc. stock performancePortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayMarket Weekly Review & Weekly High Conviction Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutPortfolio Performance Summary & Weekly High Return Stock Opportunities - newser.com
Why The Narrative Around Amneal Is Shifting Amid Analyst Revisions and Recent FDA Approvals - Yahoo Finance
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneMarket Sentiment Summary & Fast Moving Stock Trade Plans - newser.com
Amneal Pharmaceuticals (AMRX): Valuation Perspective After FDA Greenlight for First Generic Omnipaque and Raised Guidance - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock By Investing.com - Investing.com Australia
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Amneal gets FDA nod for Iohexol Injection (AMRX:NASDAQ) - Seeking Alpha
FDA approves Amneal’s generic iohexol injection for imaging procedures - Investing.com
Amneal Receives U.S. FDA Approval for Iohexol Injection - The Manila Times
Amneal (NASDAQ: AMRX) expects to launch first generic Omnipaque iohexol in Q1 2026 - Stock Titan
Published on: 2025-11-13 05:47:52 - newser.com
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD By Investing.com - Investing.com Philippines
Is Amneal Pharmaceuticals Inc. stock resilient to inflationTrade Volume Summary & Long-Term Growth Plans - newser.com
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):